Get the Stockscreener App
145.13
8.86%
11.81
Moderna Inc stock is traded at $145.13, with a volume of 87.01M.
It is up +8.86% in the last 24 hours and up +143.26% over the past month.
Moderna is a commercial-stage biotech that was founded in 2010 and had its initial public offering in December 2018. The firm's mRNA technology was rapidly validated with its covid vaccine, which was authorized in the United States in December 2020. Moderna had 35 mRNA development candidates in clinical studies as of August 2025. Programs span a wide range of therapeutic areas, including infectious disease, oncology, cardiovascular disease, and rare genetic diseases.
See More
Previous Close:
$133.32
Open:
$133.11
24h Volume:
87.01M
Relative Volume:
7.26
Market Cap:
$57.94B
Revenue:
$2.23B
Net Income/Loss:
$-3.19B
P/E Ratio:
-17.82
EPS:
-8.1462
Net Cash Flow:
$-1.60B
1W Performance:
+129.20%
1M Performance:
+143.26%
6M Performance:
+191.02%
1Y Performance:
+453.51%
1-Day Range:
$132.42
$159.47
1-Week Range:
$62.13
$176.66
52-Week Range:
$22.28
$176.66
Moderna Inc Stock (MRNA) Company Profile
Name
Moderna Inc
Sector
Industry
Phone
(617) 714-6500
Address
325 BINNEY STREET, CAMBRIDGE
Compare MRNA vs VRTX, REGN, ARGX, RVMD
| Stocks | Price | Market Cap | Revenue | Net Income | Cash Flow | EPS |
|---|---|---|---|---|---|---|
MRNA
Moderna Inc
|
145.13 | 53.23B | 2.23B | -3.19B | -1.60B | -8.1462 |
VRTX
Vertex Pharmaceuticals Inc
|
548.05 | 136.93B | 12.34B | 4.34B | 3.71B | 16.87 |
REGN
Regeneron Pharmaceuticals Inc
|
834.04 | 85.11B | 14.92B | 4.42B | 3.79B | 41.04 |
ARGX
Argen X Se Adr
|
1,039.78 | 64.95B | 4.16B | 1.29B | 734.26M | 19.58 |
RVMD
Revolution Medicines Inc
|
209.46 | 45.38B | 742.00K | -1.37B | -1.07B | -7.0731 |
Moderna Inc Stock (MRNA) Upgrades & Downgrades
| Date | Action | Analyst | Rating Change |
|---|---|---|---|
| Jan-28-26 | Resumed | Barclays | Equal Weight |
| Jan-07-26 | Resumed | UBS | Neutral |
| Dec-12-25 | Initiated | Jefferies | Hold |
| Mar-13-25 | Initiated | Citigroup | Neutral |
| Feb-18-25 | Downgrade | Barclays | Overweight → Equal Weight |
| Jan-29-25 | Downgrade | Goldman | Buy → Neutral |
| Dec-18-24 | Downgrade | Argus | Buy → Hold |
| Dec-10-24 | Resumed | BofA Securities | Underperform |
| Nov-19-24 | Initiated | Berenberg | Hold |
| Nov-18-24 | Upgrade | HSBC Securities | Hold → Buy |
| Nov-15-24 | Initiated | Wolfe Research | Underperform |
| Oct-17-24 | Initiated | Bernstein | Mkt Perform |
| Sep-13-24 | Downgrade | JP Morgan | Neutral → Underweight |
| Sep-13-24 | Downgrade | Jefferies | Buy → Hold |
| Sep-13-24 | Downgrade | Oppenheimer | Outperform → Perform |
| Aug-28-24 | Upgrade | HSBC Securities | Reduce → Hold |
| Aug-07-24 | Upgrade | Deutsche Bank | Sell → Hold |
| Aug-05-24 | Downgrade | RBC Capital Mkts | Outperform → Sector Perform |
| Feb-26-24 | Downgrade | HSBC Securities | Hold → Reduce |
| Jan-02-24 | Upgrade | Oppenheimer | Perform → Outperform |
| Nov-29-23 | Initiated | Canaccord Genuity | Hold |
| Nov-03-23 | Upgrade | HSBC Securities | Reduce → Hold |
| Nov-02-23 | Downgrade | Deutsche Bank | Hold → Sell |
| Aug-04-23 | Downgrade | TD Cowen | Outperform → Market Perform |
| Aug-03-23 | Downgrade | Deutsche Bank | Buy → Hold |
| Jul-24-23 | Initiated | William Blair | Mkt Perform |
| Jul-14-23 | Initiated | HSBC Securities | Reduce |
| Jun-26-23 | Upgrade | UBS | Neutral → Buy |
| Apr-26-23 | Initiated | Guggenheim | Neutral |
| Mar-13-23 | Upgrade | TD Cowen | Market Perform → Outperform |
| Mar-02-23 | Initiated | RBC Capital Mkts | Outperform |
| Feb-24-23 | Downgrade | SVB Securities | Market Perform → Underperform |
| Dec-19-22 | Upgrade | Jefferies | Hold → Buy |
| Dec-14-22 | Downgrade | Chardan Capital Markets | Buy → Neutral |
| Oct-21-22 | Upgrade | SVB Leerink | Underperform → Mkt Perform |
| Sep-08-22 | Upgrade | Deutsche Bank | Hold → Buy |
| Feb-01-22 | Upgrade | Redburn | Sell → Neutral |
| Jan-26-22 | Upgrade | Deutsche Bank | Sell → Hold |
| Jan-21-22 | Upgrade | BofA Securities | Underperform → Neutral |
| Jan-21-22 | Initiated | UBS | Neutral |
| Dec-07-21 | Initiated | Cowen | Market Perform |
| Nov-09-21 | Initiated | Wolfe Research | Outperform |
| Oct-22-21 | Initiated | Deutsche Bank | Sell |
| Oct-15-21 | Upgrade | Piper Sandler | Neutral → Overweight |
| Aug-06-21 | Downgrade | Oppenheimer | Outperform → Perform |
| Aug-06-21 | Downgrade | Piper Sandler | Overweight → Neutral |
| Jul-15-21 | Reiterated | Jefferies | Hold |
| Feb-01-21 | Downgrade | BofA Securities | Neutral → Underperform |
| Dec-16-20 | Downgrade | Jefferies | Buy → Hold |
| Dec-16-20 | Downgrade | Morgan Stanley | Overweight → Equal-Weight |
| Dec-09-20 | Downgrade | Needham | Buy → Hold |
| Nov-23-20 | Initiated | Wells Fargo | Equal Weight |
| Nov-17-20 | Downgrade | BMO Capital Markets | Outperform → Market Perform |
| Sep-08-20 | Downgrade | SVB Leerink | Mkt Perform → Underperform |
| Jul-23-20 | Initiated | SVB Leerink | Mkt Perform |
| Jul-20-20 | Downgrade | JP Morgan | Overweight → Neutral |
| Jul-13-20 | Initiated | Jefferies | Buy |
| Jun-30-20 | Initiated | Argus | Buy |
| Jun-08-20 | Initiated | Barclays | Overweight |
| Apr-30-20 | Initiated | BMO Capital Markets | Outperform |
| Mar-05-20 | Downgrade | BofA/Merrill | Buy → Neutral |
| Dec-03-19 | Resumed | BofA/Merrill | Buy |
| Oct-25-19 | Initiated | ROTH Capital | Buy |
| Apr-05-19 | Initiated | Chardan Capital Markets | Buy |
View All
Moderna Inc Stock (MRNA) Latest News
Moderna cancer vaccine breakthrough revives hopes for biotech turnaround By Investing.com - Investing.com Nigeria
SLS, IBRX Stocks In Focus: Analyst Says Moderna-Merck Cancer Vaccine Success ‘Bodes Well’ For Oncology - Stocktwits
Health Care Up as Moderna Leads Biotech HigherHealth Care Roundup - marketscreener.com
Moderna Shares (NASDAQ:MRNA) Finish Landmark Week, Surging 70% Over Wall Street Consensus - TechStock²
SLS Stock Clocks Three Straight Weeks Of Gains On Cancer Vaccine Spillover, REGAL Trial Data Anticipation - Yahoo Finance
Moderna Soars 129% for the Week | Closing Bell - marketscreener.com
Moderna Stock Erupts As Cancer Vaccine Trial Delivers Historic Win - StocksToTrade
Moderna Stock Explodes As Phase 3 Cancer Vaccine Data Hits - timothysykes.com
Moderna, Robinhood, Marvell, Tesla, SpaceX, and More Stocks That Explain Today’s Market - Barron's
Bessent's Bond Rescue, Bitcoin's Best Week Since 2023Coinbase Global (NASDAQ:COIN) - Benzinga
Moderna (MRNA) Cancer Vaccine Success Won’t Lift All mRNA Stocks - Barron's
Moderna Just Doubled on a Massive Cancer Breakthrough. Here’s Why MRNA Stock Isn’t a Buy Yet. - Barchart.com
Moderna’s Cancer Vaccine Breakthrough Sends Stocks Soaring - cheddar.com
Why Moderna’s mRNA Cancer Drug Hype Has Gone Too Far - Barron's
If You Invested $1,000 In Moderna Stock at IPO, Here's How Much You'd Have Now - TradingView
Moderna Stock Explodes As Landmark Cancer Trial Sparks Re‑Rating - StocksToTrade
Moderna Stock Explodes After Landmark Cancer Vaccine Breakthrough - timothysykes.com
How a Big Bet on Cancer Vaccines Brought Moderna Back from the Brink - WSJ
Moderna (NASDAQ:MRNA) Price Target Raised to $77.00 at JPMorgan Chase & Co. - MarketBeat
After Moderna’s Big News, Here Are Three Biotechs to Watch - TheStreet Pro
Moderna Inc Stock (MRNA) Moved Up by 14.01% on Aug 21: What Signal Does It Send? - TradingKey
Moderna, Robinhood, Marvell, Tesla, SpaceX, and More Stocks That Explain Today's Market -- Barrons.com - Moomoo
Moderna jumps 18% on investor optimism - Breakingthenews.net
Moderna Options Flash Extreme Caution as Cancer Vaccine Fuels Stock Surge: Options Chatter - Moomoo
Moderna Cancer Vaccine Could Redefine the CompanyModerna (NASDAQ:MRNA) - Benzinga
Moderna (NASDAQ:MRNA) Sees Strong Trading Volume on Analyst Upgrade - MarketBeat
Merck & Co Inc Stock (MRK) Moved Up by 3.41% on Aug 21: Facts Behind the Movement - TradingKey
Moderna Rallies 8%, BioNTech Climbs 4% as the mRNA Trade Whipsaws for a Third Session - Yahoo Finance
Moderna and Merck’s cancer vaccine clears phase 3; Ultragenyx lands gene therapy nod - Pharma Voice
Moderna, Merck mRNA cancer vaccine prevents melanoma from returning in trial - KXAN Austin
Rx Rundown: Moderna, Merck, LEO Pharma and more - Medical Marketing and Media
Moderna’s 177% Surge Has Investors Asking What Comes Next - MarketBeat
Moderna’s personalized mRNA shot could reshape the fight against skin cancer — but it may also be overhyped - MarketWatch
Moderna and Merck cancer vaccine success paves way for future - EMJ
Pharma Bro Admits 'Playing Around' With MRNA Short At $80 Before it Exploded 177% Following Cancer Vax Trials— ‘I Bet You a Bunch of People Got Fired’ - Yahoo Finance
Meeder Advisory Services Inc. Buys New Shares in Moderna, Inc. $MRNA - MarketBeat
MEXC Lists Ondo Tokenized Stock Moderna (MRNAON), Expanding Access to U.S. Biotech Exposure - TradingView
A Cancer Vaccine Is Closer Than Ever - Bloomberg.com
Amid the chip bear market, healthcare is breaking out: Chart of the Day - Yahoo Finance
JPMorgan Adjusts Price Target on Moderna to $77 From $40, Keeps Underweight Rating - marketscreener.com
Elon Musk Says mRNA Has ‘Tremendous’ Potential After Moderna, Merck Cancer Vaccine Breakthrough — MRNA Stock Falls Over 11% in Premarket (UPDATED) - Yahoo Finance
Personalized cancer vaccine launched by Moderna: Drug firm’s shares soar more than 100% — should you buy? - Yahoo! Finance Canada
Mitsubishi UFJ Asset Management Co. Ltd. Acquires New Holdings in Moderna, Inc. $MRNA - MarketBeat
983,450 Shares in Moderna, Inc. $MRNA Bought by Deutsche Bank AG - MarketBeat
Moderna (MRNA) Clears A Phase 3 Milestone, Is The Upside Already Priced In? - Yahoo Finance
5 Reasons Why Moderna Stock Jumped 170% and How Far It Can Go - CryptoRank
Watch Moderna, Merck Cancer Vax Gives Hope - Bloomberg.com
Moderna, Merck develop vaccine that could help fight against melanoma - cbs8.com
Moderna (MRNA) Sees Stock Surge After Positive Melanoma Trial Re - GuruFocus
FDA approves Moderna's mRNA seasonal flu vaccineABC News - ABC News - Breaking News, Latest News and Videos
Moderna's Comeback Is Finally Taking Shape -- and There May Be More Upside Ahead - Yahoo Finance
Moderna Inc Stock (MRNA) Financials Data
Revenue
Net Income
Cash Flow
EPS
0.16%
1.07%
Open in Yahoo
|
Open in Google
|
Open in Finviz
|
Open in MarketWatch
|
Open in EDGAR
|
Open in Reuters
Cap:
|
Volume (24h):